Guardant Health Inc. (GH) saw its stock price surge 11.11% in after-hours trading on Wednesday, following the release of its impressive third-quarter financial results that significantly surpassed analyst expectations. The precision oncology company demonstrated robust growth and improved financial performance across key metrics.

Guardant Health reported Q3 revenue of $265.2 million, marking a 39% year-over-year increase and handily beating the analyst consensus estimate of $235.7 million. The company's adjusted earnings per share (EPS) came in at -$0.39, substantially better than the expected -$0.76. Additionally, adjusted EBITDA loss narrowed to $45.5 million, outperforming the estimated loss of $54.7 million.

The strong quarterly performance was driven by impressive growth in oncology test volume, which increased by 40% compared to the previous year. Notably, the company's Shield screening tests generated $24.1 million in revenue, up from just $1 million in the prior year period. In light of these results, Guardant Health raised its full-year 2025 revenue guidance to $965-$970 million, up from the previous forecast of $915-$925 million. This upward revision, coupled with the company's strategic collaborations to expand Shield access nationwide, has boosted investor confidence in Guardant Health's growth trajectory and market position in the competitive precision oncology sector.